We investigated the relationship between immune infiltration and imaging metrics derived from breast MRI in patients with HER2+ breast cancer treated with trastuzumab. Fourteen patients with localized HER2+ breast cancer were imaged with diffusion-weighted and dynamic contrast-enhanced (DCE-) MRI prior to and ~2 weeks after a run-in dose of trastuzumab. Pre-treatment ADC and change in DCE-MRI peak percent enhancement were both significantly associated with immune response as characterized by change in level of tumor infiltrating lymphocytes.
This abstract and the presentation materials are available to members only; a login is required.